Early benefit assessments Archives — Page 8 of 9 — German Market Access

Regular and abbreviated early benefit assessments – Is this the end of orphan drug privileges?

This is the first article in a series about maybe the most important topic influencing market access in Germany: HTAs or early

In July 2021, we had heard that the G-BA had agreed to joint EU HTAs coming to Germany. Now, on 14 December

Manufacturers of drugs or medical devices can apply for a consultation meeting with the G-BA before submitting a dossier. This consultation offers

On 6 December 2021, Prof. Dr. Karl Lauterbach was announced as the new German health minister. This might mean quite a lot

The new government in Germany is formed as a coalition of the three parties, SDP, FDP and the Green Party. At the

The gene therapies Zolgensma and Libmeldy, both, are targeting very rare, severe, genetic diseases in children. The G-BA has now assessed the

The G-BA has 13 voting members forming the so-called plenum. The representatives of care providers are only entitled to vote on topics

In the recent early benefit assessment of nivolumab, the G-BA not only accepted the submitted ITC, but this also resulted in a

The antiviral drug remdesivir (brand name: Veklury) has been the first drug targeting COVID-19, which has undergone an early benefit assessment. It

The G-BA has now completed its benefit assessment of the CAR-T therapy, Tecartus, which is indicated for the treatment of mantle cell